GILEAD SCIENCES (NASDAQ: GILD) Breakout Swing Trading Idea

GILEAD SCIENCES INC (GILD)       87.925   +0.09 (+0.11%)


News Image
GILEAD SCIENCES (NASDAQ: GILD) Breakout Swing Trading Idea4 months ago - Chartmill

TRADING IDEA (Momentum Swing Trading Breakout)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read the full profile here.

STRATEGY

Breakout Swing Trading Idea

  1. clean breakout during last trading session, wide range bullish bar closed near the high of day (+5.2%)
  2. strongly increased buying volume
  3. closing price above current daily resistance level
  4. long term trend (weekly chart), price breakout above sideways trading channel

Last earnings: 2022-08-02

Next earnings: 2022-10-26



ACTUAL SETUP

  • Buy Stop | $66.36
  • Limit | $66.50
  • Stoploss | $63.44
  • Target | first and second target area on weekly chart

ADDITIONAL INFO/TIPS

Disclaimer: These trading ideas are merely to demonstrate what ChartMill is capable of and shows some typical results of a breakout filter. It is in no way actual financial advise to invest or trade in these stocks. The author has no pre-existing position in any of these stocks.

Back

GILD Links

GILD News

News Image3 hours ago - The Motley FoolThe Top Healthcare Stocks to Buy With $100

Triple-digit growth and innovation go hand-in-hand with these companies.

News Image20 hours ago - Market News VideoIntuit Takes Over #73 Spot From Gilead SciencesNews Image21 hours ago - Yahoo FinanceUPDATE 1-FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab

Eli Lilly and Co's COVID-19 drug bebtelovimab is not currently authorized for emergency use in the United States, the Food and Drug Administration said, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron. Wednesday's announcement takes away authorization from the last COVID-19 monoclonal antibody treatment, leaving Pfizer Inc's antiviral drug Paxlovid, Merck's Lagevrio and Gilead Sciences' Veklury as treatments for the disease, besides convalescent plasma for some patients. AstraZeneca Plc's monoclonal antibody Evusheld is also authorized for protection against COVID-19 infection in some people.

News Imagea day ago - The Motley Fool2 Reasons This Stock Could Outperform in 2023

It would be a continuation of this year's showing.

News Imagea day ago - The Motley FoolThese 3 Stocks Are Rallying While the Rest of the Market Plunges

Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.

News Image2 days ago - Seeking AlphaGilead gets European approval for use of HIV drug Biktarvy in children

Gilead Sciences (GILD) on Tuesday said the European Commission had approved an expansion for its HIV drug Biktarvy for the use in children

News Image2 days ago - Gilead Sciences, Inc.European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric PopulationsNews Image3 days ago - Investor's Business DailyGilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges

Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher.

News Image3 days ago - Seeking AlphaGilead and Arcus issue update from mid-stage trial for lung cancer therapy (NASDAQ:GILD)

Gilead Sciences (GILD) and partner Arcus Biosciences (RCUS) announced Monday the results from their Phase 2 ARC-7 study for lung cancer therapies containing anti-TIGIT and anti-PD-1...

News Image3 days ago - Arcus BiosciencesGilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung CancerNews Image8 days ago - Investor's Business DailySee Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch

Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching.

News Image9 days ago - The Motley Fool2 Reasons to Buy AbbVie Stock and 1 Reason to Sell

The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem.

Follow us for more